Compugen Ltd.

Sector:

Health Technology

Industry:

Biotechnology

Employees:

73

Background

Compugen Ltd. (CGEN) is a micro-cap stock in the healthcare sector. As a biotech company, it engages in the research, development, and sale of therapeutic and diagnostic biomarker products. These include proteins and monoclonal antibodies.

CGEN reached a high of $19.90 in August 2020. After that, it began a pronounced downtrend that it has yet to recover from. The stock's price fell to a low of $0.66 in September 2022. It has been in oversold territory on the relative strength index (RSI) since January 2022. Although there is still a possibility that CGEN might make new lows, the price is showing a positive divergence from the moving average convergence divergence (MACD). As price is making lower lows, the MACD is rising and thereby not confirming.

Overview

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

About Them

Compugen is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platforms to identify novel drug targets and new biological pathways and develop therapeutics in the field of cancer immunotherapy. Recognizing the potential of immuno-oncology to shift the cancer treatment landscape, they chose to focus on the discovery of new drug targets to extend the reach of cancer immunotherapies to new patient populations.

Their approach is rooted in more than a decade of pioneering multidisciplinary research involving the development of innovative computational approaches for the discovery of novel drug targets.

This approach, which resulted in three programs in clinical development, is constantly evolving and allows us to discover novel drug targets and develop a deep understanding of cancer biology. Integrated into their computational discovery capabilities, they have extensive drug target validation processes and drug development capabilities that employ rigorous experimentation. This allows them to identify promising immunotherapy drug candidates and to translate our in-silico findings into potentially first-in-class therapeutics with the potential to improve patient outcomes.